HLB's Liver Cancer Drug Gets FDA’s Orphan Drug Status

HLB’s Liver Cancer Drug Gets FDA’s Orphan Drug Status

According to reports, HLB’s anticancer drug candidate rivoceranib has won an orphan drug designation from the U.S. Food and Drug…

Read More »